Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004992 · ClinicalTrials.gov registry record · Phase 3
Diabetes Prevention Program
A Phase 3 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 3
- Development phase
- 3,234
- Enrollment target
NCT00004992: Completed Phase 3 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
NCT00004992 is a Phase 3 study that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 3,234 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (319% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004992, a Phase 3 study, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,234 participants
- Enrollment target
Study Summary
The Diabetes Prevention Program is a nationwide clinical study to answer the question: Can Type 2 diabetes (also called noninsulin-dependent or adult-onset diabetes) be prevented or delayed? The study has recruited volunteers, who are at high risk of developing diabetes, at twenty-five medical centers in the United States. It is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, and other Institute and corporate sponsors. Researchers will evaluate the efficacy of a lifestyle intervention and a pharmacological intervention in preventing or delaying Type 2 diabetes in persons with impaired glucose tolerance (IGT). Each person in the study will be followed for 3 to 6 years.
Primary Outcome
Diabetes was diagnosed on the basis of an annual oral glucose-tolerance test or a semiannual fasting plasma glucose test, according to the 1997 criteria of the American Diabetes Association
Interventions
- DRUG Placebo
- DRUG Metformin
- BEHAVIORAL Intensive lifestyle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,234 participants |
| Start Date | 1996-07 |
| Est. Completion | 2001-04 |
| Phase | Phase 3 |
What the finished NCT00004992 record still lists
NCT00004992 is an interventional study that assigns participants to a tested intervention. Its 3,234 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (319% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00004992 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004992 about?
NCT00004992 is a clinical study titled "Diabetes Prevention Program". The Diabetes Prevention Program is a nationwide clinical study to answer the question: Can Type 2 diabetes (also called noninsulin-dependent or adult-onset diabetes) be prevented or delayed? The study has recruited volunteers, who are at high risk of developing diabetes, at twenty-five medical cente...
What is the current status of trial NCT00004992?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,234 participants. The study started on 1996-07. Estimated completion is 2001-04.
What interventions are being tested in trial NCT00004992?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), Intensive lifestyle (BEHAVIORAL).
Who is sponsoring clinical trial NCT00004992?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00004992's enrollment target sits among peer trials
3,234 73rd of 2000 higher than 1,928 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06953375 · 3,250 participants · NA
Implementation of Neuromuscular Electrical Stimulation After Total Knee Arthroplasty
- NCT06587529 · 3,218 participants · NA
Rigorous Evaluation of the READY to Stand Curriculum to Prevent the Commercial Sexual Exploitation of Children
- NCT06760507 · 3,209 participants · NA
Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
- NCT04077762 · 3,266 participants · NA
Radial Vs. State-Of-The-Art Femoral Access for Bleeding and Access Site Complication Reduction in Cardiac Catheterization (REBIRTH)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia